To evaluate the effects of canrenone as add-on therapy in patients already treated with angiotensin converting-enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARBs) and hydrochlorothiazide at the maximum dosage (25 mg/day).
Efficacy and Safety of Two Dosages of Canrenone as Add-On Therapy in Hypertensive Patients Taking Ace-Inhibitors or Angiotensin II Receptor Blockers and Hydrochlorothiazide at Maximum Dosage in a Randomized Clinical Trial: The ESCAPE-IT Trial
GUASTI, LUIGINA;
2016-01-01
Abstract
To evaluate the effects of canrenone as add-on therapy in patients already treated with angiotensin converting-enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARBs) and hydrochlorothiazide at the maximum dosage (25 mg/day).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
